Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

BioLineRx (BLRX) Consolidated Net Income: 2012-2024

Historic Consolidated Net Income for BioLineRx (BLRX) over the last 13 years, with Dec 2024 value amounting to -$11.3 million.

  • BioLineRx's Consolidated Net Income rose 45.04% to -$2.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$7.7 million, marking a year-over-year increase of 80.04%. This contributed to the annual value of -$11.3 million for FY2024, which is 76.25% up from last year.
  • Latest data reveals that BioLineRx reported Consolidated Net Income of -$11.3 million as of FY2024, which was up 76.25% from -$47.5 million recorded in FY2023.
  • BioLineRx's 5-year Consolidated Net Income high stood at -$11.3 million for FY2024, and its period low was -$47.5 million during FY2023.
  • For the 3-year period, BioLineRx's Consolidated Net Income averaged around -$28.6 million, with its median value being -$27.0 million (2022).
  • As far as peak fluctuations go, BioLineRx's Consolidated Net Income slumped by 76.03% in 2023, and later spiked by 76.25% in 2024.
  • Over the past 5 years, BioLineRx's Consolidated Net Income (Yearly) stood at -$21.3 million in 2020, then dropped by 11.61% to -$23.8 million in 2021, then dropped by 13.58% to -$27.0 million in 2022, then crashed by 76.03% to -$47.5 million in 2023, then skyrocketed by 76.25% to -$11.3 million in 2024.